Neomorph: Funding, Investors & Team (Sep 2026)
Neomorph develops protein degradation therapies targeting diseases not addressed by conventional treatments. The company designs molecular strategies that induce proximity between proteins to enable selective degradation through natural cellular pathways. Its work focuses on discovering compounds that can modulate protein function by removing or altering specific targets within cells. The organization applies computational design, structural biology, and chemical biology to support drug discovery efforts. It advances programs across multiple therapeutic areas where controlled protein degradation may provide new treatment options.
Neomorph has raised $100M across 1 funding round on record, the most recent a Series B of $100M announced in Apr 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Neomorph Company Profile and Key Stats
Latest funding round on record: Apr 2026.
Neomorph Funding Rounds
Neomorph Founders and Leadership Team
Contact details for the Neomorph team: 1 of 1 has an email address on file.
Start 14-day free trial →Neomorph Funding Compared to Other Biotechnology Startups
Neomorph's latest round of $100M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Neomorph in Biotechnology and San Diego
Companies Similar to Neomorph
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Neomorph Funding FAQs
What does Neomorph do?
Neomorph develops protein degradation therapies targeting diseases not addressed by conventional treatments. The company designs molecular strategies that induce proximity between proteins to enable selective degradation through natural cellular pathways. Its work focuses on discovering compounds that can modulate protein function by removing or altering specific targets within cells. The organization applies computational design, structural biology, and chemical biology to support drug discovery efforts. It advances programs across multiple therapeutic areas where controlled protein degradation may provide new treatment options.
How much funding has Neomorph raised?
Neomorph has raised $100M across 1 round on record. The most recent is a Series B of $100M announced in Apr 2026.
When did Neomorph last raise funding?
Neomorph's most recent funding round on record is a Series B of $100M, announced in Apr 2026.
Who founded Neomorph?
FundedIQ lists Phil Chamberlain (Founder) at Neomorph.
Where is Neomorph headquartered?
Neomorph is based in San Diego, California, United States.
How many employees does Neomorph have?
Neomorph is in the 101-250 employee band.
How does Neomorph's funding compare to other Biotechnology startups?
Neomorph's latest round of $100M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Neomorph Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Neomorph is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.